首页> 外文OA文献 >Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations

【2h】

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations

机译：预处理直接胆红素和总胆固醇是高级非小细胞肺癌患者的全面存活的显着预测因子EGFR突变

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yanwei Zhang; Jianlin Xu; Yuqing Lou; Song Hu; Keke Yu; Rong Li; Xueyan Zhang; Bo Jin; Baohui Han;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EGFR敏感突变的晚期非小细胞肺癌患者EGFR-TKIs原发性耐药相关基因突变分析 [J] . 王芳, 刁夏尧, 张晓, 癌症（英文版） . 2020,第009期
2. Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations [J] . Zhang Yanwei, Xu Jianlin, Lou Yuqing, International Journal of Cancer =: Journal International du Cancer . 2017,第7期

机译：预处理直接胆红素和总胆固醇是晚期非小细胞肺癌患者的全面存活的显着预测因子EGFR突变
3. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. [J] . Taron M Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第5期

机译：厄洛替尼治疗的EGFR突变晚期非小细胞肺癌患者的治疗前EGFR T790M突变和BRCA1 mRNA表达。
4. Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer (vol 30, pg 433, 2012) [J] . Su Journal of Clinical Oncology . 2015,第18期

机译：预处理表皮生长因子受体（EGFR）T790M突变可预测非小细胞肺癌患者中较短的EGFR酪氨酸激酶抑制剂反应持续时间（第30卷，第433页，2012年）
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
7. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) [O] . Yi-Long Wu, Vera Hirsh, Lecia V. Sequist, -1

机译：EGFR突变类型是否会影响晚期EGFR突变阳性非小细胞肺癌患者的患者报告结局？两项将阿法替尼与化疗进行比较的大型三期研究的分析（LUX-Lung 3和LUX-Lung 6）
8. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2) [O] . Cadranel, Jacques, Mauguen, Audrey, Faller, Michele M., 2012

机译：在法国前瞻性队列研究中，系统性的EGFR和KRAS突变评估对厄洛替尼治疗的晚期非小细胞肺癌患者无进展生存和总体生存的影响（ERMETIC项目第2部分）

Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations

著录项

引文网络

相似文献

相关主题

期刊订阅